About X4 Pharmaceuticals, Inc.
https://www.x4pharma.comX4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.
CEO
Paula Ragan
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-04-28 | Reverse | 1:30 |
| 2019-03-14 | Reverse | 1:6 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:10.68M
Value:$40.25M
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC
Shares:2.44M
Value:$9.19M
BVF INC/IL
Shares:2.23M
Value:$8.42M
Summary
Showing Top 3 of 60
About X4 Pharmaceuticals, Inc.
https://www.x4pharma.comX4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.76M ▼ | $28.92M ▲ | $-29.82M ▼ | -1.69K% ▼ | $-0.69 ▲ | $-27.36M ▼ |
| Q2-2025 | $1.97M ▼ | $27.88M ▼ | $-25.74M ▼ | -1.3K% ▼ | $-3.47 ▼ | $-23.12M ▼ |
| Q1-2025 | $28.81M ▲ | $33.53M ▼ | $282K ▲ | 0.98% ▲ | $0.04 ▲ | $2.99M ▲ |
| Q4-2024 | $1.43M ▲ | $36.85M ▲ | $-39.82M ▼ | -2.78K% ▲ | $-6 ▼ | $-36.99M ▼ |
| Q3-2024 | $560K | $34.83M | $-36.7M | -6.55K% | $-5.4 | $-34M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $122.42M ▲ | $163.56M ▲ | $101.94M ▲ | $61.62M ▲ |
| Q2-2025 | $62.95M ▼ | $105.17M ▼ | $101.2M ▼ | $3.97M ▼ |
| Q1-2025 | $86.95M ▼ | $130.01M ▼ | $107.07M ▼ | $22.94M ▲ |
| Q4-2024 | $102.06M ▼ | $146.45M ▼ | $124.3M ▲ | $22.15M ▼ |
| Q3-2024 | $134.98M | $178.16M | $118.54M | $59.62M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-29.82M ▼ | $-27.82M ▲ | $-28.67M ▼ | $86.91M ▲ | $30.41M ▲ | $-27.82M ▲ |
| Q2-2025 | $-25.74M ▼ | $-29.9M ▼ | $23.11M ▲ | $5.63M ▲ | $-1.02M ▲ | $-29.9M ▼ |
| Q1-2025 | $282K ▲ | $-12.37M ▲ | $-3.14M ▲ | $0 ▼ | $-15.43M ▲ | $-15.37M ▲ |
| Q4-2024 | $-39.82M ▼ | $-32.99M ▲ | $-8.62M ▲ | $135K ▲ | $-41.73M ▲ | $-33.04M ▲ |
| Q3-2024 | $-36.7M | $-34.03M | $-15.93M | $0 | $-49.8M | $-34.12M |
Revenue by Products
| Product | Q2-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 License and Other Revenue | $0 ▲ | $0 ▲ | $30.00M ▲ | $0 ▼ |
 Product | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Product Returns | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Paula Ragan
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-04-28 | Reverse | 1:30 |
| 2019-03-14 | Reverse | 1:6 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:10.68M
Value:$40.25M
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC
Shares:2.44M
Value:$9.19M
BVF INC/IL
Shares:2.23M
Value:$8.42M
Summary
Showing Top 3 of 60